<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01290757</url>
  </required_header>
  <id_info>
    <org_study_id>1160.117</org_study_id>
    <secondary_id>2010-022966-28</secondary_id>
    <nct_id>NCT01290757</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Two Different Capsule Types of Dabigatran</brief_title>
  <official_title>Bioequivalence of Two Different Capsule Types of 150 mg Dabigatran Etexilate Made From Two Different Drug Product Batches, Following Oral Administration in Healthy Male and Female Volunteers (Open-label, Randomised, Single Dose, Replicate Design in a Two Treatments, Four Periods Crossover Phase I Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this Phase I trial is to demonstrate the bioequivalence of two capsules of
      dabigatran etexilate made from two different drug product batches.

      The reference batch is dabigatran etexilate hard capsules 150 mg using the currently approved
      capsule shell (Qualicaps). The test batch is dabigatran etexilate 150 mg hard capsules using
      a new capsule shell (Capsugel). The test batch is the drug product intended for future
      commercial use.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve 0 to tz (AUC0-tz) of Total Dabigatran</measure>
    <time_frame>60 hours</time_frame>
    <description>Area under the concentration-time curve of total dabigatran in plasma from time 0 to the time of the last quantifiable data point, adjusted for treatment, period and sequence (all fixed effects), and random subject effect.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Measured Concentration (Cmax) of Total Dabigatran in Plasma</measure>
    <time_frame>60 hours</time_frame>
    <description>Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve 0 to Infinity (AUC0-∞) of Total Dabigatran.</measure>
    <time_frame>60 hours</time_frame>
    <description>Area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 extrapolated to infinity. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz of Free Dabigatran.</measure>
    <time_frame>60 hours</time_frame>
    <description>Area under the concentration-time curve of free dabigatran in plasma from time 0 to the time of the last quantifiable data point. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Free Dabigatran in Plasma.</measure>
    <time_frame>60 hours</time_frame>
    <description>Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ of Free Dabigatran.</measure>
    <time_frame>60 hours</time_frame>
    <description>Area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 extrapolated to infinity. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dabigatran etexilate 150 mg (T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsugel (T), oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran etexilate 150 mg (R)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Qualicaps (R), oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate</intervention_name>
    <description>150 mg Capsugel (T)</description>
    <arm_group_label>Dabigatran etexilate 150 mg (T)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate</intervention_name>
    <description>150 mg Qualicaps (R)</description>
    <arm_group_label>Dabigatran etexilate 150 mg (R)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males and females according to the following criteria: Based upon a complete
             medical history, including the physical examination, vital signs (blood pressure (BP),
             pulse rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests

          2. Age =21 and = 55 years

          3. Body Mass Index (BMI) =18.5 and BMI = 29.9 kg/m^2

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP) and the local legislation

        Exclusion criteria:

          1. Clinically relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular,
             metabolic, immunological or hormonal disorders

          2. Clinically relevant surgery of gastrointestinal tract or evidence of significant
             gastrointestinal motility problems that could affect absorption of the drug

          3. Diseases of the central nervous system (included but not limited to any kind of
             seizures, stroke or psychiatric disorders) within the past 6 month

          4. Any history or evidence of blood dyscrasia, hemorrhagic diathesis, severe
             thrombocytopenia, cerebrovascular hemorrhage, bleeding tendencies associated with
             active ulceration or overt bleeding of gastrointestinal, respiratory or genitourinary
             tract or any disease or condition with hemorrhagic tendencies

          5. History of relevant orthostatic hypotension, fainting spells or blackouts

          6. Chronic or relevant acute infections

          7. History of allergy/hypersensitivity (including drug allergy in particular to study
             drug or its excipients) which is deemed relevant to the trial as judged by the
             investigator

          8. Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 10 days prior to administration
             or during the trial

          9. Alcohol abuse (more than 20 g/day)

         10. Drug abuse

         11. Any laboratory value outside the reference range that is of clinical relevance
             (especially hemoglobin, thrombocytes, prothrombin time (PT) and Activated Partial
             Thromboplastin Time (Measure of the clotting time) (aPTT) or positive drug or virus
             screening

         12. Planned surgeries within four weeks following the end-of study examination

         13. Recent or contemplated diagnostic or therapeutic procedures with potential for
             uncontrollable bleeding within 14 days before or after end-of study examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.117.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2011</study_first_submitted>
  <study_first_submitted_qc>February 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2011</study_first_posted>
  <results_first_submitted>April 18, 2012</results_first_submitted>
  <results_first_submitted_qc>May 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 29, 2012</results_first_posted>
  <last_update_submitted>May 8, 2014</last_update_submitted>
  <last_update_submitted_qc>May 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>In this crossover study, subjects were randomly assigned to one of the 2 sequences, with 2 treatment arms. In general terms, Ref-Test-Ref-Test and Test-Ref-Test-Ref. The aim was bioequivalence comparing (Ref) Dabigatran 150mg in the currently approved capsule shell (Qualicaps) to the test of Dabigatran 150mg in a new shell (Capsugel).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence: Qualicaps - Capsugel - Qualicaps - Capsugel</title>
          <description>Dabigatran 150mg in currently approved Qualicaps, followed by Dabigatran 150mg in new Capsugel, followed by Dabigatran 150mg in currently approved Qualicaps, followed by Dabigatran 150mg in new Capsugel (RTRT)</description>
        </group>
        <group group_id="P2">
          <title>Sequence: Capsugel - Qualicaps - Capsugel - Qualicaps</title>
          <description>Dabigatran 150mg in new Capsugel, followed by Dabigatran 150mg in currently approved Qualicaps, followed by Dabigatran 150mg in new Capsugel, followed by Dabigatran 150mg in currently approved Qualicaps (TRTR)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set includes all patients who received at least one study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Sequence: Qualicaps - Capsugel - Qualicaps - Capsugel</title>
          <description>Dabigatran 150mg in currently approved Qualicaps, followed by Dabigatran 150mg in new Capsugel, followed by Dabigatran 150mg in currently approved Qualicaps, followed by Dabigatran 150mg in new Capsugel (RTRT)</description>
        </group>
        <group group_id="B2">
          <title>Sequence: Capsugel - Qualicaps - Capsugel - Qualicaps</title>
          <description>Dabigatran 150mg in new Capsugel, followed by Dabigatran 150mg in currently approved Qualicaps, followed by Dabigatran 150mg in new Capsugel, followed by Dabigatran 150mg in currently approved Qualicaps (TRTR)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="90"/>
            <count group_id="B3" value="180"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.8" spread="10.1"/>
                    <measurement group_id="B2" value="39.4" spread="9.1"/>
                    <measurement group_id="B3" value="39.6" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve 0 to tz (AUC0-tz) of Total Dabigatran</title>
        <description>Area under the concentration-time curve of total dabigatran in plasma from time 0 to the time of the last quantifiable data point, adjusted for treatment, period and sequence (all fixed effects), and random subject effect.</description>
        <time_frame>60 hours</time_frame>
        <population>This subject set, the pharmacokinetic set (PKS), includes all subjects of the treated set who provide at least one evaluable observation for at least one of the three PK endpoints of total dabigatran, which is obtained in a period without important protocol violations relevant to the evaluation of bioequivalence.</population>
        <group_list>
          <group group_id="O1">
            <title>Capsugel</title>
            <description>Dabigatran 150mg in new Capsugel</description>
          </group>
          <group group_id="O2">
            <title>Qualicaps</title>
            <description>Dabigatran 150mg in currently approved Qualicaps</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve 0 to tz (AUC0-tz) of Total Dabigatran</title>
          <description>Area under the concentration-time curve of total dabigatran in plasma from time 0 to the time of the last quantifiable data point, adjusted for treatment, period and sequence (all fixed effects), and random subject effect.</description>
          <population>This subject set, the pharmacokinetic set (PKS), includes all subjects of the treated set who provide at least one evaluable observation for at least one of the three PK endpoints of total dabigatran, which is obtained in a period without important protocol violations relevant to the evaluation of bioequivalence.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1147.64" spread="32.32"/>
                    <measurement group_id="O2" value="908.48" spread="49.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Capsugel minus Qualicaps</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence (BE). Scaled average BE is rejected, if the calculated upper 95% confidence limit of the linearized criterion is positive.</non_inferiority_desc>
            <param_type>Upper 95% CI of the linearized criterion</param_type>
            <param_value>-0.082</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <estimate_desc>Linearized regulatory criterion according to Tothfalusi et al (Pharmaceutical Research, 2001). The square of the difference in treatment responses divided by within-subject variance of the reference formulation minus square of ln(1.25)/0.25</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Capsugel vs Qualicaps</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence (BE). Bioequivalence is accepted if 90% confidence interval lies within the common BE margins (80% and 125%).</non_inferiority_desc>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>126.33</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>119.45</ci_lower_limit>
            <ci_upper_limit>133.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Measured Concentration (Cmax) of Total Dabigatran in Plasma</title>
        <description>Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.</description>
        <time_frame>60 hours</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Capsugel</title>
            <description>Dabigatran 150mg in new Capsugel</description>
          </group>
          <group group_id="O2">
            <title>Qualicaps</title>
            <description>Dabigatran 150mg in currently approved Qualicaps</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Measured Concentration (Cmax) of Total Dabigatran in Plasma</title>
          <description>Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.</description>
          <population>PKS</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.44" spread="31.10"/>
                    <measurement group_id="O2" value="107.13" spread="49.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Capsugel minus Qualicaps</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence (BE). Scaled average BE is rejected, if the calculated upper 95% confidence limit of the linearized criterion is positive.</non_inferiority_desc>
            <param_type>Upper 95% CI of the linearized criterion</param_type>
            <param_value>-0.085</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <estimate_desc>Linearized regulatory criterion according to Tothfalusi et al (Pharmaceutical Research, 2001). The square of the difference in treatment responses divided by within-subject variance of the reference formulation minus square of ln(1.25)/0.25</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Capsugel vs Qualicaps</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence (BE). Bioequivalence is accepted if 90% confidence interval lies within the common BE margins (80% and 125%).</non_inferiority_desc>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>125.49</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>118.69</ci_lower_limit>
            <ci_upper_limit>132.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve 0 to Infinity (AUC0-∞) of Total Dabigatran.</title>
        <description>Area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 extrapolated to infinity. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.</description>
        <time_frame>60 hours</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Capsugel</title>
            <description>Dabigatran 150mg in new Capsugel</description>
          </group>
          <group group_id="O2">
            <title>Qualicaps</title>
            <description>Dabigatran 150mg in currently approved Qualicaps</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve 0 to Infinity (AUC0-∞) of Total Dabigatran.</title>
          <description>Area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 extrapolated to infinity. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.</description>
          <population>PKS</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1175.05" spread="30.81"/>
                    <measurement group_id="O2" value="941.99" spread="46.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Capsugel vs Qualicaps</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence (BE). Bioequivalence is accepted if 90% confidence interval lies within the common BE margins (80% and 125%).</non_inferiority_desc>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>124.74</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>118.32</ci_lower_limit>
            <ci_upper_limit>131.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-tz of Free Dabigatran.</title>
        <description>Area under the concentration-time curve of free dabigatran in plasma from time 0 to the time of the last quantifiable data point. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.</description>
        <time_frame>60 hours</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Capsugel</title>
            <description>Dabigatran 150mg in new Capsugel</description>
          </group>
          <group group_id="O2">
            <title>Qualicaps</title>
            <description>Dabigatran 150mg in currently approved Qualicaps</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-tz of Free Dabigatran.</title>
          <description>Area under the concentration-time curve of free dabigatran in plasma from time 0 to the time of the last quantifiable data point. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.</description>
          <population>PKS</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="856.31" spread="33.15"/>
                    <measurement group_id="O2" value="678.43" spread="50.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Capsugel vs Qualicaps</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence (BE). Bioequivalence is accepted if 90% confidence interval lies within the common BE margins (80% and 125%).</non_inferiority_desc>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>126.22</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>119.36</ci_lower_limit>
            <ci_upper_limit>133.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Free Dabigatran in Plasma.</title>
        <description>Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.</description>
        <time_frame>60 hours</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Capsugel</title>
            <description>Dabigatran 150mg in new Capsugel</description>
          </group>
          <group group_id="O2">
            <title>Qualicaps</title>
            <description>Dabigatran 150mg in currently approved Qualicaps</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Free Dabigatran in Plasma.</title>
          <description>Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.</description>
          <population>PKS</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.66" spread="31.34"/>
                    <measurement group_id="O2" value="85.12" spread="50.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Capsugel vs Qualicaps</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence (BE). Bioequivalence is accepted if 90% confidence interval lies within the common BE margins (80% and 125%).</non_inferiority_desc>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>125.30</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>118.42</ci_lower_limit>
            <ci_upper_limit>132.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-∞ of Free Dabigatran.</title>
        <description>Area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 extrapolated to infinity. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.</description>
        <time_frame>60 hours</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Capsugel</title>
            <description>Dabigatran 150mg in new Capsugel</description>
          </group>
          <group group_id="O2">
            <title>Qualicaps</title>
            <description>Dabigatran 150mg in currently approved Qualicaps</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ of Free Dabigatran.</title>
          <description>Area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 extrapolated to infinity. Adjusted for treatment, period and sequence (all fixed effects), and random subject effect.</description>
          <population>PKS</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="888.86" spread="31.20"/>
                    <measurement group_id="O2" value="714.01" spread="47.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Capsugel vs Qualicaps</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence (BE). Bioequivalence is accepted if 90% confidence interval lies within the common BE margins (80% and 125%).</non_inferiority_desc>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>124.49</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>118.11</ci_lower_limit>
            <ci_upper_limit>131.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Qualicaps</title>
          <description>Dabigatran 150mg in Qualicaps</description>
        </group>
        <group group_id="E2">
          <title>Capsugel</title>
          <description>Dabigatran 150mg in Capsugel</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

